gabexate has been researched along with HELLP Syndrome in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
HELLP Syndrome: A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumura, T | 1 |
| Aoyama, Y | 1 |
| Ichihara, H | 1 |
| Koh, S | 1 |
| Mugitani, A | 1 |
| Hayakawa, H | 1 |
| Yukioka, K | 1 |
| Kinoshita, D | 1 |
| Nakagawa, M | 1 |
| Yamazaki, N | 1 |
1 other study available for gabexate and HELLP Syndrome
| Article | Year |
|---|---|
[Successful treatment with the combination of recombinant human soluble thrombomodulin and gabexate mesilate in three patients with obstetric disseminated intravascular coagulation].
Topics: Abruptio Placentae; Adult; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Female | 2011 |